Giant Cell Tumour of the Skull Base Treated with Surgery, Stereotactic Radiosurgery and Denosumab: Case Report and Review of Literature - Open Access Library Journal

OALibJ > Vol.4 No.5, May 2017

Volume 4, Issue 5 (May 2017)

ISSN Print: 2333-9705 ISSN Online: 2333-9721

Google-based Impact Factor: 1.18 Citations

Giant Cell Tumour of the Skull Base Treated with Surgery, Stereotactic Radiosurgery and Denosumab: Case Report and Review of Literature ()

HTML XML

Download as PDF (Size: 1451KB) PP. 1-7

DOI: 10.4236/oalib.1103571 1,368 Downloads 3,042 Views Citations

Author(s)

Jorge H. Guajardo¹, Cuauhtemoc de la Peña², Maria F. Gonzalez^3*, Cesar Gonzalez⁴, Carlos Cuilty⁵, Horacio Decanini⁶

Affiliation(s)

¹Departments of Neurosurgery, Neuro-Oncology Unit, Hospital de Alta Especialidad Chistrus Muguerza, Monterrey, Nuevo León Mexico.
²Radiosurgery, Neuro-Oncology Unit, Hospital de Alta Especialidad Chistrus Muguerza, Monterrey, Nuevo León Mexico.
³Neuro-Oncology, Neuro-Oncology Unit, Hospital de Alta Especialidad Chistrus Muguerza, Monterrey, Nuevo León Mexico.
⁴Oncology, Neuro-Oncology Unit, Hospital de Alta Especialidad Chistrus Muguerza, Monterrey, Nuevo León Mexico.
⁵Otolaryngology, Neuro-Oncology Unit, Hospital de Alta Especialidad Chistrus Muguerza, Monterrey, Nuevo León Mexico.
⁶Pathology, Neuro-Oncology Unit, Hospital de Alta Especialidad Chistrus Muguerza, Monterrey, Nuevo León Mexico.

ABSTRACT

Giant cell tumours (GCT) of the skull base account for approximately 1% of all GTC of the bone. Despite being considered as a benign neoplasm, they are locally aggressive with high recurrence rates after incomplete surgery. Due to the small number of cases reported in skull base, standardized treatment remains unclear. Even with new surgical techniques, a complete resection in skull base tumours is not always possible without functional compromise. Therefore, adjuvant therapy is essential to enhance local control and quality of life. We described a case treated successfully with primary surgery followed by Cyberknife stereotactic radiosurgery (SRS) and denosumab with a 48-month follow-up. To the best of our knowledge, the usage of combined therapy, SRS and denosumab, in skull base GCT has not been previously described.

KEYWORDS

Giant Cell Tumour, Skull Base, Stereotactic Radiosurgery, Denosumab

Share and Cite:

Guajardo, J. , de la Peña, C. , Gonzalez, M. , Gonzalez, C. , Cuilty, C. and Decanini, H. (2017) Giant Cell Tumour of the Skull Base Treated with Surgery, Stereotactic Radiosurgery and Denosumab: Case Report and Review of Literature. Open Access Library Journal, 4, 1-7. doi: 10.4236/oalib.1103571.

Cited by